他汀类药物与脑卒中的研究进展

[1] Stroke protection by3-hydroxy-3-methylglutary1(HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Endres M,,Laufs U,Huang Z,et al. Proc Nat Acad Sci US A . 1998

[2] The pleiotropic effects of statins. Calabro P,,Yeh ET. Current Opinion in Cardiology . 2005

[3] ML-236A,ML-236B,and ML-236C,newinhibitors of cholesterogenesis produced by penicilli-umcitrinium. Endo A,,Kuroda M,Tsujita Y. Journal of Antibiotics . 1976

[4] Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-argi-nine after chronic statin treat ment. Yamada M,,Huang Z,Dalkara T,et al. Journal of Cerebral Blood Flow and Metabolism . 2000

[5] An HMG-CoAreduc-tase inhibitor,cerivastatin,suppresses growth of macrophages expressing matrix metalloproteinases andtissue factor in vivo andin vitro. Aikawa M,,Rabkin E,Sugiyama S,et al. Circulation . 2001

[6] Statins in stroke prevention and carotid atherosclerosis:systematic review and up-to-date meta-analysis. Amarenco P,,Labreuche J,Lavallee P,et al. Stroke . 2004

[7] Design and baseline characteristics of the stroke prevention by aggressive reductionin cholesterol levels(SPARCL)study. Amarenco P,,Bogousslavsky J,Callahan AS,et al. Cerebro-vasc Dis . 2003

[8] Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial. Nissen SE,Tuzcu EM,Schoenhagen P,et al. The Journal of The American Medical Association . 2004

[9] Effect of the HMG-CoAreductase inhibitors on blood pressure in patients with es-sential hypertension and pri mary hypercholesterolemia. Glorioso N,,Troffa C,Filigheddu F,et al. Journal of Hypertension . 1999

[10] C-reactive proteinlev-els and outcomes after statin therapy. Ridker PM,,Cannon CP,Morrow D,et al. The New England Journal of Medicine . 2005

[1] Stroke protection by3-hydroxy-3-methylglutary1(HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Endres M,,Laufs U,Huang Z,et al. Proc Nat Acad Sci US A . 1998

[2] The pleiotropic effects of statins. Calabro P,,Yeh ET. Current Opinion in Cardiology . 2005

[3] ML-236A,ML-236B,and ML-236C,newinhibitors of cholesterogenesis produced by penicilli-umcitrinium. Endo A,,Kuroda M,Tsujita Y. Journal of Antibiotics . 1976

[4] Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-argi-nine after chronic statin treat ment. Yamada M,,Huang Z,Dalkara T,et al. Journal of Cerebral Blood Flow and Metabolism . 2000

[5] An HMG-CoAreduc-tase inhibitor,cerivastatin,suppresses growth of macrophages expressing matrix metalloproteinases andtissue factor in vivo andin vitro. Aikawa M,,Rabkin E,Sugiyama S,et al. Circulation . 2001

[6] Statins in stroke prevention and carotid atherosclerosis:systematic review and up-to-date meta-analysis. Amarenco P,,Labreuche J,Lavallee P,et al. Stroke . 2004

[7] Design and baseline characteristics of the stroke prevention by aggressive reductionin cholesterol levels(SPARCL)study. Amarenco P,,Bogousslavsky J,Callahan AS,et al. Cerebro-vasc Dis . 2003

[8] Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial. Nissen SE,Tuzcu EM,Schoenhagen P,et al. The Journal of The American Medical Association . 2004

[9] Effect of the HMG-CoAreductase inhibitors on blood pressure in patients with es-sential hypertension and pri mary hypercholesterolemia. Glorioso N,,Troffa C,Filigheddu F,et al. Journal of Hypertension . 1999

[10] C-reactive proteinlev-els and outcomes after statin therapy. Ridker PM,,Cannon CP,Morrow D,et al. The New England Journal of Medicine . 2005